Literature DB >> 26104925

Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses.

David I Rosenthal1, Clifton D Fuller2, Lester J Peters3, Howard D Thames4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26104925      PMCID： PMC5955397          DOI： 10.1016/j.ijrobp.2015.02.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  18 in total

1.  Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.

Authors:  Heather E Newlin; Robert J Amdur; Charles E Riggs; Christopher G Morris; Jessica M Kirwan; William M Mendenhall
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

2.  Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx.

Authors:  K K Ang; L J Peters; R S Weber; M H Maor; W H Morrison; C D Wendt; B W Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-12       Impact factor: 7.038

3.  Local control of T3 carcinomas after accelerated fractionation: a look at the "gap".

Authors:  C C Wang; J Efird; B Nakfoor; P Martins
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-06-01       Impact factor: 7.038

4.  Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).

Authors:  V A Marcial; T F Pajak; C Chang; L Tupchong; J Stetz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-01       Impact factor: 7.038

5.  Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.

Authors:  Jonathan J Beitler; Qiang Zhang; Karen K Fu; Andy Trotti; Sharon A Spencer; Christopher U Jones; Adam S Garden; George Shenouda; Jonathan Harris; Kian K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-07       Impact factor: 7.038

6.  Dose-response relationships for late radiation effects in the head and neck: regarding the analysis of the RTOG 8313 trial, Fu et al. IJROBP 32:577-588; 1995.

Authors:  S M Bentzen; H D Thames
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-01-15       Impact factor: 7.038

7.  ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.

Authors:  J D Cox; T F Pajak; V A Marcial; L Coia; M Mohiuddin; K K Fu; H Selim; P Rubin; H Ortiz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-06       Impact factor: 7.038

Review 8.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

9.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors:  Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

10.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.